Funding
← Back to your selection

SR One

Activity from announced rounds

Activity in this selectionJan 31, 2026 · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$250M
2 disclosed · full round size, not this investor’s share

By stage

Series A2

By primary sector

Biotech1
Healthtech1

By country

United States2

Rounds

2 in this selection
AirNexis Therapeutics

AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.

$200MSeries A
Role not disclosed
Poplar Therapeutics

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$50MSeries A
Role not disclosed